Bivictrix Therapeutics PLC on Thursday said its Bi-Cygni antibody-drug conjugate, BVX001, showed survival rates more than doubled in a pre-clinical model of acute myeloid leukaemia.

The...

Related Keywords

, Alliance News , Bivictrix Therapeutics , Alliance News Ltd , Executive Officer Tiffany Thorn , Sabrina Penty , All Rights , Markets ,